References
- U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: USDHHS Office of the Surgeon General, 2004
- National Osteoporosis Foundation. Available at: http://www.nof.org [Last accessed 2009 October 13]
- Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 Suppl):505-11S
- Greenspan SL, Harris ST, Bone H, et al. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 2000;61:2731-6
- Ibandronate (Boniva). Product Label, Roche GlaxoSmithKlein, Nutley, NJ, March, 2005
- Alendronate (Fosamax). Product Label, Merck & Co, Inc., Whitehouse Station, NJ, July 2005
- Risedronate (Actonel), Product Label, Proctor & Gamble Pharmaceuticals, Cincinnati, OH, May 2005
- Calcitonin-salmon for injection (Miacalcin), Novartis Pharmaceuticals Corporation, East Hanover, NJ, November 2002
- Calcitonin-salmon nasal spray (Miacalcin), Novartis Pharmaceuticals Corporation, East Hanover, NJ, June 2006
- Raloxifene (Evista). Product Label, Eli Lilly and Company, Indianapolis, IN, 2007
- Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
- Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95
- Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
- Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97
- Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
- Cadarette SM, Katz JN, Brookhart MA, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637-46
- Foster SA, Foley KA, Meadows ES, et al. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health 2008;8:24
- Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53
- Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4